Vitamin D Shows Slight, Inconsistent Benefit for Metabolic Syndrome in Review of Eight Trials

Vitamin D supplementation produced small and inconsistent improvements in some components of metabolic syndrome, according to a systematic review of randomized controlled trials published in Frontiers in Nutrition. The review, led by Haha Alzarooni, Falak Zeb and Dimitrios Papandreou of the University of Sharjah, found that while supplements reliably raised blood levels of 25-hydroxyvitamin D, their effects on triglycerides, insulin resistance, blood pressure, cholesterol and fasting glucose varied widely from trial to trial, and the overall certainty of the evidence was limited by a high proportion of studies with methodological concerns.

Metabolic syndrome is not a single disease but a cluster of five cardiometabolic abnormalities: central obesity, elevated triglycerides, reduced HDL-cholesterol, high blood pressure and elevated fasting glucose. Under the widely used harmonized definition, a diagnosis requires any three of the five. A recent modeling analysis spanning 198 countries estimated that global prevalence of the syndrome roughly doubled between 2000 and 2023, reaching an estimated 1.54 billion affected adults by 2023, with prevalence rising further with age, urbanization and income level. At its center lies insulin resistance and dysfunctional visceral adipose tissue, which secretes pro-inflammatory cytokines and adipokines that impair insulin signaling throughout the body.

Vitamin D has long been suspected to play a role in this cluster. The nutrient is synthesized in skin upon ultraviolet-B exposure or obtained from limited dietary sources, and it undergoes sequential conversion first to 25-hydroxyvitamin D, the main circulating form, and then to the active hormone calcitriol. Receptors for vitamin D are found not only in calcium-regulating tissues but also in pancreatic beta cells, skeletal muscle and adipose tissue. Proposed links to metabolic syndrome components include support for insulin secretion, promotion of glucose uptake in muscle, modulation of adipogenesis and lipid metabolism, and negative regulation of the renin-angiotensin-aldosterone system, which has been tied experimentally to blood pressure.

Observational evidence has been strikingly consistent: a global pooled analysis of close to 8 million participants estimated that around three-quarters of the world’s population falls below the 30 ng/mL threshold often used to define insufficiency, and a meta-analysis in adults with metabolic syndrome found that vitamin D deficiency was associated with significantly higher odds of having the syndrome, with an odds ratio of 1.84. Interventional evidence, however, has not borne out these signals consistently. One trial using weekly 50,000 IU doses reported significant reductions in triglycerides and improved insulin sensitivity, while a separate pilot trial in a similar population found no effect on any cardiovascular risk factor examined, and a trial restricted to postmenopausal women found improvement in the overall risk profile.

To address this inconsistency, the review team searched PubMed/MEDLINE, Embase, Web of Science and the Cochrane Central Register of Controlled Trials following PRISMA guidelines, with the review registered in PROSPERO under CRD420261421121. From 1,240 identified records, 930 remained after duplicate removal, 150 went to full-text assessment, and ten randomized trials initially met eligibility criteria. One single-arm pilot study without a placebo or dietary-instruction comparator was excluded, and a further trial was dropped after data extraction because its measured outcomes, serum calcium and parathyroid hormone, did not correspond to any pre-specified metabolic syndrome parameter. Eight randomized controlled trials, totaling 634 participants, formed the final narrative synthesis.

The included trials were conducted in Brazil, Iran, Pakistan, Greece, India and Iraq, enrolled adults aged roughly 30 to 65 years, and lasted from 8 to 36 weeks. All eight used vitamin D3, with daily dosing regimens ranging from 1,000 to 2,000 IU, two trials using weekly regimens of 50,000 to 60,000 IU, and one trial administering two bolus doses of 200,000 IU at weeks 0 and 4. Because of substantial clinical and methodological heterogeneity, the authors planned a narrative synthesis rather than a meta-analysis from the outset, comparing patterns of effect across studies grouped by baseline vitamin D status and supplementation dose rather than performing formal statistical subgroup analysis.

The results were deliberately mixed. Vitamin D supplementation consistently increased serum 25(OH)D concentrations across all trials, confirming an effective biological response. Two studies demonstrated significant reductions in triglycerides, and one showed significant reductions in fasting insulin and HOMA-IR, an index of insulin resistance. One trial reported significant reductions in waist circumference and body mass index, and two studies reported improvements in inflammatory markers, including a significant reduction in interleukin-6 in one trial and reductions in hs-CRP and pro-oxidant-antioxidant balance in the metabolic syndrome subgroup of another. By contrast, blood pressure, HDL-cholesterol and fasting glucose showed no consistent change across the majority of trials, a pattern the authors describe as the dominant one in the evidence base rather than a collection of isolated negative results.

Patterns by dose and baseline status were suggestive but explicitly exploratory. Trials enrolling participants with confirmed baseline vitamin D deficiency and trials using higher doses equivalent to roughly 7,000 to 8,500 IU per day tended to show stronger improvements in metabolic parameters, while studies using lower doses of 2,000 IU per day or less, or a short 8-week bolus regimen, reported largely null results on insulin resistance and lipid profiles. Classified by the 4,000 IU per day threshold, four trial-outcomes used higher doses and all four reported a statistically significant improvement in at least one measured outcome, while of the four using lower doses, three reported a significant improvement in a core outcome and one showed no significant change in any measured outcome. Baseline vitamin D status relative to the 20 ng/mL deficiency threshold was not consistently reported across trials and could not be classified with the same confidence, and no trial was powered for formal subgroup comparison.

The certainty of the evidence is further constrained by risk of bias. Using the Cochrane Collaboration Risk of Bias Tool, the reviewers judged one trial, Ferreira 2020, to be at low risk of bias across all seven domains, four trials to have some concerns, most often driven by unclear allocation concealment or incomplete outcome data, and three trials to be at high risk, most frequently because of inadequate blinding of participants and personnel. Seven of the eight trials therefore had some concerns or high risk of bias in at least one domain. The authors also note that whether the statistically significant biomarker changes are clinically meaningful is uncertain: broader meta-analyses in metabolic syndrome populations disagree on both the direction and magnitude of vitamin D’s effect on triglycerides, and the HDL-cholesterol increase reported in one included trial was statistically significant but modest in absolute terms and confined to participants who were vitamin D-replete at baseline rather than deficient.

The review’s conclusion is cautious. Vitamin D supplementation shows slight benefit for specific metabolic syndrome components, particularly among vitamin D-deficient adults, but effects were inconsistent across trials and metabolic parameters, and substantial variability in study design, dosing strategies and population characteristics limits definitive conclusions. The authors recommend that future research prioritize adequately powered, multicenter randomized trials that stratify participants a priori by baseline vitamin D status and supplementation dose, use standardized dosing protocols and sufficient follow-up duration, control more consistently for diet, physical activity and sun exposure, and report age-stratified outcomes. Until such trials are completed, the findings should be regarded as exploratory signals warranting further investigation rather than evidence of clinically actionable benefit, and the authors state that standardized dosing protocols, larger trials and longer follow-up are needed before vitamin D supplementation can be recommended as a component of metabolic syndrome management.

Subject of Research: The effects of oral vitamin D supplementation on metabolic syndrome components in adults, examined through a systematic review of randomized controlled trials stratified by baseline vitamin D status and supplementation dose.

Article Title: Effect of vitamin D supplementation on metabolic syndrome parameters in adults: a systematic review of randomized controlled trials exploring the role of baseline vitamin D status and supplementation dose

Article References: Alzarooni, H., Zeb, F., & Papandreou, D. (2026). Effect of vitamin D supplementation on metabolic syndrome parameters in adults: a systematic review of randomized controlled trials exploring the role of baseline vitamin D status and supplementation dose. Frontiers in Nutrition, 13, 1974621. https://doi.org/10.3389/fnut.2026.1974621

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1974621

Keywords: vitamin D supplementation, metabolic syndrome, systematic review, randomized controlled trials, insulin resistance, triglycerides, HOMA-IR, 25-hydroxyvitamin D, risk of bias, dose-response, inflammatory markers, narrative synthesis